301207 Hualan Biological Vaccine Inc.
- 19.00
- -0.22-1.14%
Hualan Biological Vaccine Inc. News
Hualan Biological Vaccine's (SZSE:301207) Shareholders Have More To Worry About Than Only Soft Earnings
Hualan Vaccine: Report for the third quarter of 2024
Hualan Vaccine (301207.SZ): Net income in the first three quarters was 0.267 billion yuan, a year-on-year decrease of 57.54%.
Galenghui October 29th | Hualan Vaccine (301207.SZ) announced the third quarter report of 2024, with the company's revenue reaching 0.957 billion yuan in the first three quarters, a year-on-year decrease of 44.28%; the net income attributable to the company's shareholders was 0.267 billion yuan, a year-on-year decrease of 57.54%; the net income attributable to the company's shareholders excluding non-recurring gains and losses was 0.196 billion yuan, a year-on-year decrease of 64.65%; the basic earnings per share was 0.4463 yuan.
We Think Hualan Biological Vaccine (SZSE:301207) Can Manage Its Debt With Ease
Hualan Vaccine (301207.SZ): Currently, there is no cooperation with foreign giants companies.
On September 20th, Gelonghui announced that Hualan Vaccine (301207.SZ) has consistently adhered to independent research and development, as well as the combination of industry, academia, and research, and has collaborated with domestic high-level universities, research institutes, and other institutions to carry out a series of cooperative research and development work. Currently, there is no collaboration with foreign giants.
HL VACCINE (301207.SZ): Among the vaccines currently in the registration process, there is still no vaccine with antibodies against monkeypox.
On September 20th, GeLongHui reported that Hualan Vaccine (301207.SZ) stated on the investor interactive platform that the company has entered the registration process for a vaccine product under research, and there is currently no vaccine with antibodies against smallpox. The company will continue to focus on cutting-edge vaccine categories and steadily advance the research and development of products under research.
Hualan Vaccine (301207.SZ) has repurchased a total of 5.6008 million shares, costing 99.1311 million yuan.
Huaren Vaccine (301207.SZ) announcement, as of August 31, 2024, the company traded through centralized bidding...
Hualan Vaccine: 2024 Semi-Annual Report
Hualan Vaccine: 2024 Semi-Annual Report Summary
Hualan Vaccine (301207.SZ): The net income in the first half of the year was 25.2744 million yuan, a year-on-year decrease of 76.65%.
On August 29th, Gelonhui announced its semi-annual report for 2024, with reported revenue of 35.529 million yuan, a year-on-year decrease of 76.25%; net income attributable to shareholders of listed companies was 25.2744 million yuan, a year-on-year decrease of 76.65%; net income attributable to shareholders of listed companies after deducting non-recurring gains and losses was -21.3215 million yuan; basic earnings per share was 0.0421 yuan.
Huawei Health Vaccine (301207.SZ) released its semi-annual performance, with a net income of 25.2744 million yuan, a year-on-year decrease of 76.65%.
Hualan Vaccine (301207.SZ) released its semi-annual report for 2024, during which the company achieved revenue of 3...
Many Still Looking Away From Hualan Biological Vaccine Inc. (SZSE:301207)
Hualan Vaccine (301207.SZ): has repurchased 0.55% of the shares.
On August 2nd, Gelon Hui announced that as of July 31st, 2024, the company has repurchased 3,320,100 shares of stock through the Shenzhen Stock Exchange trading system through centralized bidding trading, accounting for 0.55% of the company's current total share capital. The highest fill price was 18.13 yuan/share and the lowest fill price was 16.23 yuan/share, with a total transaction amount of 57.5927 million yuan (excluding trading fees). The implementation of the repurchase meets the requirements of relevant laws and regulations and complies with the company's established repurchase plan.
Declining Stock and Decent Financials: Is The Market Wrong About Hualan Biological Vaccine Inc. (SZSE:301207)?
Hualan Vaccine (301207.SZ): repurchased 0.37% of the shares.
On June 20, 2024, Hualan Vaccines (301207.SZ) announced that it has repurchased company shares through a share repurchase specific securities account using centralized bidding trading. As of June 30, 2024, the company accumulatively repurchased 2,210,000 shares through the Shenzhen Stock Exchange trading system using centralized bidding trading, accounting for 0.37% of the company's total share capital. The highest fill price was 18.13 yuan/share, the lowest fill price was 17.07 yuan/share, and the total transaction amount was 38,747,200 yuan (excluding transaction fees). The above repurchase has been implemented.
Hualan Vaccine (301207.SZ): First repurchased 0.0616% of shares.
On June 20, Huallan Vaccine (301207.SZ) announced that on June 20, 2024, the company repurchased 370,000 shares of the company through a stock repurchase special securities account in a centralized bidding trading method, accounting for 0.0616% of the total share capital of the company. The highest transaction price was 17.65 yuan/share and the lowest transaction price was 17.47 yuan/share, with a total transaction amount of 6,494,645.00 yuan (excluding transaction fees). The implementation of this repurchase plan complies with relevant laws and regulations and meets the company's established repurchase plan.
Hualan Biological Vaccine (SZSE:301207) Could Be A Buy For Its Upcoming Dividend
Hualan Biological Vaccine to Buy Back Up to 200 Million Yuan Worth of Shares
Annual equity distribution for Hualan Vaccine (301207.SZ) in 2023: 6 yuan per 10 shares, with stock dividends recorded on June 13th.
Huahai Vaccines (301207.SZ) issued a notice that the company's annual equity distribution plan for 2023 is: based on the total existing share capital of the company, distribute CNY 6 in cash (including tax) for every 10 shares to all shareholders. The equity distribution registration date is June 13, 2024, and the ex-rights and ex-dividend date is June 14, 2024.
Hualan Biological Vaccine Chairman Proposes Up to 200 Million Yuan Buyback
No Data